THE ROLE OF POSITRON EMISSION TOMOGRAPHY IN ONCOLOGY AND OTHER WHOLE-BODY APPLICATIONS

被引：74

作者：

HAWKINS, RA

HOH, C

GLASPY, J

CHOI, Y

DAHLBOM, M

REGE, S

MESSA, C

NIETSZCHE, E

HOFFMAN, E

SEEGER, L

MADDAHI, J

PHELPS, ME

机构：

[1] UNIV CALIF LOS ANGELES,SCH MED,US DOE,NUCL MED LAB,LOS ANGELES,CA 90024

[2] UNIV CALIF LOS ANGELES,SCH MED,BIOMED & ENVIRONM SCI LAB,LOS ANGELES,CA 90024

[3] UNIV CALIF LOS ANGELES,SCH MED,CRUMP INST BIOL IMAGING,LOS ANGELES,CA 90024

[4] UNIV CALIF LOS ANGELES,SCH MED,DIV HEMATOL & ONCOL,LOS ANGELES,CA 90024

来源：

SEMINARS IN NUCLEAR MEDICINE | 1992年 / 22卷 / 04期

关键词：

D O I：

10.1016/S0001-2998(05)80121-7

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Imaging and quantifying biochemical and physiological processes with PET clearly has major potential significance for all organ systems and many disease states. Although the full utility and potential of emerging new applications of PET in organs other than the heart and brain must be demonstrated in basic and clinical research studies, the rapidly accumulating aggregate experience in oncology in particular, and in other organ systems and disease states as well, indicates that PET is now truly becoming a modality of both clinical and investigative use for the body as a whole as well as for specific organ systems. Wholebody PET FDG imaging (Fig 9) illustrates the potential of biochemical imaging to map the distribution of cancer throught the body. With the growing list of radiopharmaceutical and quantitative techniques applicable to cancer studies with PET, this field will continue to realize significant growth. © 1991 W.B. Saunders Company. All rights reserved.

引用

页码：268 / 284

页数：17

共 140 条

[1] CLINICAL-ASSESSMENT OF THERAPEUTIC EFFECTS ON CANCER USING F-18 2-FLUORO-2-DEOXY-D-GLUCOSE AND POSITRON EMISSION TOMOGRAPHY - PRELIMINARY-STUDY OF LUNG-CANCER [J].